Author:
Kasuma Desfrina,Soeroso Noni Novisari,Tarigan Setia Putra,Syahruddin Elisna
Abstract
Background: EGFR mutation is a genetic disorder that is often observed and examined in Non-Small Cell Lung Carcinoma. EGFR mutation detection aims to predict sensitivity to EGFR-TKI and acts as first-line therapy. Targeted therapy with EGFR-TKI can increase the survival rate of patients with Non-Small Cell Lung Cancer compared to chemotherapy. This study aims to obtain data on the survival rate of patients with Non-Small Cell Lung Carcinoma who received targeted therapy at H. Adam Malik Hospital.
Methods: This study is a descriptive study with a retrospective cohort design carried out at the Oncology Polyclinic at RSUP H Adam Malik Medan for 5 years, from January 2014 to December 2018. The subjects of this study were all patients with lung cancer type adenocarcinoma who had received therapy with generation 1 or 2 EGFR TKI.
Results: 99 patients were included as subjects of this study. From the study, the most influential factors on lung cancer were gender, age, and smoking addiction. The study consisted of 60.6% male, 92.9% of the respondents aged 40 years and over, 56.5% active, and 43.4% passive smokers and 41.4% of the respondents with severe Brinkman index. The 30-month survival rate of EGFR-TKI (Gefitinib) patients treated with NSCLC Adenocarcinoma (Gefitinib) from 2014 to 2018 at H. Adam Malik Hospital Medan was 6.3% with a median survival of 7 months. The duration of progression-free survival in patients receiving Erlotinib therapy was 6.6 months (6.6 ± 2.51 months), while the length of progression-free survival for patients treated with Gefitinib was 9.1 months (9.1 ± 6.9 months). The results of statistical tests showed that there was no difference in progression-free survival rate between those who received Erlotinib and Gefitinib (P = 0.82).
Conclusion: The 30-month survival rate of lung adenocarcinoma patients treated with EGFR-TKI from 2014 to 2018 was 6.1% with a median survival of 7 months. Those who received Erlotinib therapy experienced Progression-Free Survival for 6.6 months and those who received Gefitinib experienced Progression-Free Survival for 9.1 months.
Publisher
Scientific Foundation SPIROSKI
Reference28 articles.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics of American 2019. CA Cancer J Clin. 2019;69(1):7-34. https://doi.org/10.3322/caac.21551 PMid:30620402
2. Agustina TS, Wulandari L. Perbandingan Respons Terapi Gefitinib pada Pasien KPKBSK EGFR Mutasi Ekson 19 dan Ekson 21. J Respir Indo. 2017;37.
3. Ahmad Y, Yousif H. Treatment of epidermal growth factor receptor mutation in non-small cell lung cancer: Current role and the future perspective. J U Unexplored Med 2017;2:39-47.
4. Ambarita AN. Response Evaluation Criteria in Solid (RECIST) Pada Pasien Kanker Paru Jenis Adenokarsinoma dengan Gen EGFR Mutasi Yang Mendapat Target Terapi di RSUP Haji Adam Malik Medan. FK USU; 2019.
5. Cella D, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, et al. Clinically meaningful improvement in symptoms and quality life for patients with non small cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol. 2005;23(13):2946-54. https://doi.org/10.1200/JCO.2005.05.153 PMid:15699477